Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.

Thank you for your patience.

To Purchase # 5227SC

5227SC 10 µg (With Carrier) $179.00
5227SF 10 µg (Carrier Free) $179.00
5227LC 50 µg (With Carrier) $529.00
5227LF 50 µg (Carrier Free) $529.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant mouse IL-17A (mIL-17A) Thr22-Ala158 (Accession #NP_034682) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-17A. All lots are greater than 98% pure.


Molecular Formula:

Recombinant mIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,377. DTT-reduced protein migrates as a 15-22 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-36 kDa protein. The expected amino-terminal TVKAA of recombinant mIL-17A was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant mIL-17A was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 0.4-1.4 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg mIL-17A.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-17A. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNFα, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4,6). Phosphorylation of some Jaks and Stats has been observed.


1.  Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.

2.  Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.

3.  Dubin, P.J. and Kolls, J.K. (2008) Immunol Rev 226, 160-71.

4.  Zrioual, S. et al. (2009) J Immunol 182, 3112-20.

5.  Wright, J.F. et al. (2008) J Immunol 181, 2799-805.

6.  Rahman, M.S. et al. (2006) J Immunol 177, 4064-71.


Entrez-Gene Id 16171
Swiss-Prot Acc. Q62386


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.